Skip to main content
. 2021 Sep 8;14:1093–1104. doi: 10.2147/JAA.S321332

Table 1.

INCS Physicochemical, Pharmacokinetic and Pharmacological Characteristics

INCSa RRAb Log Pc Therapeutic Dosed, µg/day Dose Volume, µL/day Bioavailabilitye, % CL, L/h Plasma AUCf for 20% Cortisol Suppression, pg/mL*h Dose for 20% Cortisol Suppression, µg/day TIg
FF 298912 4.1712 11062,63 20063 0.5062 6512 848 11,095 101
FP 177512 3.8912 20064 400 [mg]64 0.5134 6912 1332 18,020 90
MF 210012 4.7312 20065 400 [mg]65 0.4632,38 5412 1126 13,215 66
CICh 120012 3.0012 20066 28066 7.473,i 22812 2158 6650 33
TAA 23312 1.8512 22067 120 4638 3712 8935 713 3.2
FLU 19012 1.3612 464/40068 800 [mg]68 5068 5812 10,953 1271 2.7
BUD 93512 2.3212 25669 20070 3138 8412 2206 562 2.2
BDPh 134512 3.2712 33671 800 [mg]71 4435,38 12012 2179 594 1.8
DEX 10072 1.68 400 75 17 6750 154 0.4

Notes: aAll in ANS formulation except CIC, which uses a MDI; bRelative to DEX where DEX affinity = 100; cValues (lipophilicity) are defined as the log10 of the octanol/water partition coefficient; dTherapeutic doses for AR for adults and children (≥12) unless further specified (for BDP >12; FLU ≥14); eF, absolute bioavailability via nasal route (nose and gut absorption) determined in healthy subjects; fPlasma AUC (F dose/CL) is the estimated daily dose that would result in 20% cortisol suppression;12 gDose for 20% cortisol suppression/therapeutic dose; hValues are for the active metabolites BMP and des-CIC; iValue calculated based on Weiswasser et al J Allergy Clin Immunol. 2008,73 using the clearance and relative to value for oral inhalation.

Abbreviations: ANS, aqueous nasal spray; AR, allergic rhinitis; AUC, area under the curve; BDP, beclomethasone dipropionate; BMP, beclomethasone 17-monopropionate; BUD, budesonide; CIC, ciclesonide; CL, plasma clearance; Des-CIC, desisobutyryl ciclesonide; DEX, dexamethasone; FF, fluticasone furoate; FLU, flunisolide; FP, fluticasone propionate; INCS, intranasal corticosteroid; MDI, metered-dose inhaler; MF, mometasone furoate; RRA, relative receptor affinity; TAA, triamcinolone acetonide; TI, therapeutic index.